Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q3 FY21 results · Oct–Dec 2020
Sun Pharma Advanced Research Company reported revenue from operations of ₹21.81 crore (up 11.3% from Q3 FY20) and net loss of ₹67.62 crore for Q3 FY21 (Oct–Dec 2020), on a standalone basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 21.81 | 19.60 | +11.3% | 17.64 | +23.6% |
| Other income | 1.60 | 0.71 | +125.4% | 2.82 | −43.3% |
| Total income | 23.41 | 20.31 | +15.3% | 20.46 | +14.4% |
| Profit before tax | (67.62) | (55.51) | Loss widened | (83.49) | Loss narrowed |
| Net profit for the period | (67.62) | (55.51) | Loss widened | (83.49) | Loss narrowed |
| EPS, basic (₹) | (2.58) | (2.12) | Loss widened | (3.19) | Loss narrowed |
| Net margin (%) | -310.0 | -283.2 | -473.3 |
Standalone
- Filed with BSE
- 09 Feb 2021, 15:43 IST
- Board meeting
- 08 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE